Development of the measure of ovarian symptoms and Treatment concerns aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 5, 2014, Pages 865-873

  King, Madeleine T ^a   Stockler, Martin R ^a   Butow, Phyllis ^a   O'Connell, Rachel ^b   Voysey, Merryn ^b   Oza, Amit M ^a   Gillies, Kim ^b   Donovan, Heidi S ^c   Mercieca Bebber, Rebecca ^a   Martyn, Julie ^b   Sjoquist, Katrin ^b   Friedlander, Michael L ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Health related quality of life; Ovarian cancer; Patient reported outcomes; Symptom benefit; Symptom index

Indexed keywords

ABDOMINAL DISCOMFORT; ARTICLE; BLOATING; CANCER PALLIATIVE THERAPY; DECREASED APPETITE; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; MEASURE OF OVARIAN SYMPTOM AND TREATMENT; NAUSEA; NAUSEA AND VOMITING; OPTIMAL PATIENT REPORTED OUTCOME MEASURE; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RELIABILITY; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VALIDITY; WEIGHT CHANGE; AGED; CANCER STAGING; FOLLOW UP; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE THERAPY; PATHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ANTINEOPLASTIC AGENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PALLIATIVE CARE; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84904092476     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000167     Document Type: Article

References (25)

1. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16:7-12.
2. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-755.
3. Friedlander ML, Stockler MR, O'Connell R, et al. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancerVa reality check! Results of stage 1 of the GCIG Symptom Benefit Study. Int J Gynecol Cancer. 2014;24:857-864.
4. Luckett T, King M, Butow P, et al. Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer. 2010;20:664-684.
5. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402-1408.
6. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
7. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M, et al. Reliability and validity of the functional assessment of cancer therapyYovarian. J Clin Oncol. 2001;19:1809-1817.
8. Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003;21:526-535.
9. Beaumont J, Yount S, Lalla D, et al. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer. 2007 ASCO Annual Meeting Proceedings, Part I, Vol 25, No 18S (June 20 Supplement), 2007. p. 18S.
10. Jensen SE, Rosenbloom SK, Beaumont JL, et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol. 2011;120:214-219.
11. Donovan HS, Ward S, Sherwood P, Serlin RC, et al. Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms. J Pain Symptom Manage. 2008;35:242-257.
12. Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603-612.
13. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
14. Herth K. Abbreviated instrument to measure hope: development and psychometric evaluation. J Adv Nurs. 1992;17:1251-1259.
15. Sjoquist KM, King MT, Friedlander ML, et al. Hope, quality of life and benefit from treatment in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancerVthe GCIG Symptom Benefit Study. Oncologist. 2013;18:1221-1228.
16. FDA, Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74:65132-65133.
17. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41:1073-1093.
18. King MT, Bell M, Costa D, et al. Responsiveness and relative statistical efficiency of QLQ-C30 versus FACT-G: implications for sample size requirements of health-related quality of life endpoints. J Clin Epidemiol. 2014;67:100-107.
19. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev PharmacoeconomicsOutcomes Res. 2011;11:171-184.
20. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102-109.
21. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249-4255.
22. Valderas JM, Kotzeva A, Espallargues M, et al. The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res. 2008;17:179-193.
23. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-2818.
24. Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30:3841-3847.
25. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.